JP6697453B2 - ユビキチン活性化酵素阻害物質及び放射線の投与 - Google Patents

ユビキチン活性化酵素阻害物質及び放射線の投与 Download PDF

Info

Publication number
JP6697453B2
JP6697453B2 JP2017523500A JP2017523500A JP6697453B2 JP 6697453 B2 JP6697453 B2 JP 6697453B2 JP 2017523500 A JP2017523500 A JP 2017523500A JP 2017523500 A JP2017523500 A JP 2017523500A JP 6697453 B2 JP6697453 B2 JP 6697453B2
Authority
JP
Japan
Prior art keywords
compound
administered
radiation
cancer
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017523500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533221A (ja
JP2017533221A5 (enExample
Inventor
ニール ベンス，
ニール ベンス，
マーク ハイヤー，
マーク ハイヤー，
マイケル ミルホレン，
マイケル ミルホレン，
ヴィヴェック サムノトラ，
ヴィヴェック サムノトラ，
ソト， セルジオ ルイス サンティリャーナ
ソト， セルジオ ルイス サンティリャーナ
ダーシャン サパル，
ダーシャン サパル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2017533221A publication Critical patent/JP2017533221A/ja
Publication of JP2017533221A5 publication Critical patent/JP2017533221A5/ja
Application granted granted Critical
Publication of JP6697453B2 publication Critical patent/JP6697453B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017523500A 2014-10-29 2015-10-23 ユビキチン活性化酵素阻害物質及び放射線の投与 Expired - Fee Related JP6697453B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462072299P 2014-10-29 2014-10-29
US62/072,299 2014-10-29
US201562199011P 2015-07-30 2015-07-30
US62/199,011 2015-07-30
PCT/US2015/057064 WO2016069393A1 (en) 2014-10-29 2015-10-23 Administration of ubiquitin-activating enzyme inhibitor and radiation

Publications (3)

Publication Number Publication Date
JP2017533221A JP2017533221A (ja) 2017-11-09
JP2017533221A5 JP2017533221A5 (enExample) 2018-11-29
JP6697453B2 true JP6697453B2 (ja) 2020-05-20

Family

ID=55858198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523500A Expired - Fee Related JP6697453B2 (ja) 2014-10-29 2015-10-23 ユビキチン活性化酵素阻害物質及び放射線の投与

Country Status (5)

Country Link
US (1) US10335411B2 (enExample)
EP (1) EP3212651B1 (enExample)
JP (1) JP6697453B2 (enExample)
TW (1) TW201628621A (enExample)
WO (1) WO2016069393A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6697453B2 (ja) 2014-10-29 2020-05-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ユビキチン活性化酵素阻害物質及び放射線の投与
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655028T3 (es) 2007-08-02 2018-02-16 Millennium Pharmaceuticals, Inc. Proceso para la síntesis de inhibidores de enzima de activación de E1
EP2525659B1 (en) * 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
EP2608669B1 (en) * 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
CA2864672C (en) 2012-02-17 2018-01-09 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
JP6697453B2 (ja) 2014-10-29 2020-05-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ユビキチン活性化酵素阻害物質及び放射線の投与

Also Published As

Publication number Publication date
WO2016069393A1 (en) 2016-05-06
JP2017533221A (ja) 2017-11-09
US20170333434A1 (en) 2017-11-23
EP3212651A4 (en) 2018-07-25
TW201628621A (zh) 2016-08-16
EP3212651B1 (en) 2021-02-24
US10335411B2 (en) 2019-07-02
EP3212651A1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
JP6697453B2 (ja) ユビキチン活性化酵素阻害物質及び放射線の投与
JP6862495B2 (ja) Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置
TWI893530B (zh) Pd‐1/pd‐l1抑制劑
JP6698648B2 (ja) ユビキチン活性化酵素阻害物質及び化学療法剤の投与
KR20230173083A (ko) Cdk 억제제 및 이의 사용 방법
KR20220049518A (ko) 피라졸로[3,4-b]피라진 shp2 포스파타제 저해제
TW202309022A (zh) 用於治療具egfr突變之癌症之胺基取代雜環
KR20200096522A (ko) 통합된 스트레스 경로의 조절제
JP2024525160A (ja) Ｐｄ－ｌ１を標的とするための方法及び組成物
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
JP2018520992A (ja) アミドで置換されているシクロヘキサン誘導体
JP2025503422A (ja) Ｐｄ－ｌ１を標的とするための方法及び組成物
CA2832374A1 (en) Imidazopyridazines as akt kinase inhibitors
TW202116770A (zh) 類鐸受體促效劑
JP5886868B2 (ja) 置換ピリミド［１，２−ｂ］インダゾールおよびＰＩ３Ｋ／ＡＫＴ経路のモジュレーターとしてのそれらの使用
WO2022036312A2 (en) Inhibitors of ack1/tnk1 tyrosine kinase
WO2022036310A2 (en) Inhibitors of ack1/tnk1 tyrosine kinase
US20190062340A1 (en) Cortistatin analogs
HK40076587A (en) Pd-1/pd-l1 inhibitors
HK40049323A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK40022913B (en) Pd-1/pd-l1 inhibitors
HK40022913A (en) Pd-1/pd-l1 inhibitors
HK1233180B (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK1233180A1 (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
NZ616270B2 (en) Imidazopyridazines as akt kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200424

R150 Certificate of patent or registration of utility model

Ref document number: 6697453

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees